VISIONEERING TECHNOLOGIES INC (VTI)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
VTI - VISIONEERING TECHNOLOGIES INC
FNArena Sector :
Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.48
Index:
FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.48
Visioneering Technologies is headquartered in Alpharetta, Georgia, USA and specialises in design, sale and distribution of NaturalVue contact lenses.
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.14
22 Nov |
0.000 OPEN $0.14 |
0.000 HIGH $0.14 |
117 LOW $0.14 |
| OTHER COMPANIES IN THE SAME SECTOR | |||
| 4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -14.9 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 13.1 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 16.1 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -5.4 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -39.80 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -58.68 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -51.97 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -42.21 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -58.68 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -58.81 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | - |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 4 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 1.55 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.0 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 0.00 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 6 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 13 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 3 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
VTI STOCK CHART
FNArena News on VTI
| 1 |
Australian Broker Call *Extra* Edition – Oct 11, 2021Oct 11 2021 - Daily Market Reports |
| 2 |
Australian Broker Call *Extra* Edition – Sep 17, 2021Sep 17 2021 - Daily Market Reports |
| 3 |
Australian Broker Call *Extra* Edition – Oct 28, 2020Oct 28 2020 - Daily Market Reports |
| 4 |
The Wrap: Regional Banks & Financial AdviceMay 26 2017 - Weekly Reports |
Latest Medical Equipment & Devices News
| 1 |
ResMed’s Bounce-Back CompleteOct 29 2024 - Australia |
| 2 |
Dr Boreham’s Crucible: Pro MedicusSep 04 2024 - Australia |
| 3 |
Pro Medicus: Don’t Stop Me NowAug 20 2024 - Technicals |
| 4 |
Dr Boreham’s Crucible: BlinklabMay 20 2024 - Small Caps |
| 5 |
ResMed Silences The DoubtersApr 29 2024 - Australia |
| 6 |
Dr Boreham’s Crucible: 4D MedicalApr 23 2024 - Small Caps |
| 7 |
Uptrend Resumed For ResMedMar 19 2024 - Technicals |
| 8 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
| 9 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |
| 10 |
Dr Boreham’s Crucible: ArtryaFeb 15 2024 - Small Caps |